

Medivir Q1 2023 - Quick Recruitment in Phase IIa

Redeye comments on Medivir's first quarter report of 2023. During the quarter, the phase IIa part in which fostrox is combined with Lenvima was initiated. Recruitment is going ahead at a fast pace.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Medivir Q1 2023 - Quick Recruitment in Phase Ila